Roivant Sciences Ltd. (NASDAQ:ROIV) COO Eric Venker Sells 218,041 Shares of Stock

Roivant Sciences Ltd. (NASDAQ:ROIV) COO Eric Venker sold 218,041 shares of the company’s stock in a transaction that occurred on Thursday, February 13th. The stock was sold at an average price of $10.42, for a total value of $2,271,987.22. Following the completion of the transaction, the chief operating officer now owns 896,869 shares of the company’s stock, valued at $9,345,374.98. The trade was a 19.56 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Eric Venker also recently made the following trade(s):

• On Tuesday, January 21st, Eric Venker sold 100,000 shares of Roivant Sciences stock. The stock was sold at an average price of $11.28, for a total value of $1,128,000.00.
• On Monday, December 30th, Eric Venker sold 177,704 shares of Roivant Sciences stock. The stock was sold at an average price of $11.54, for a total value of $2,050,704.16.
• On Friday, December 27th, Eric Venker sold 176,900 shares of Roivant Sciences stock. The stock was sold at an average price of $11.82, for a total value of $2,090,958.00.
• On Friday, December 20th, Eric Venker sold 100,000 shares of Roivant Sciences stock. The shares were sold at an average price of $11.49, for a total value of $1,149,000.00.
• On Wednesday, November 20th, Eric Venker sold 100,000 shares of Roivant Sciences stock. The shares were sold at an average price of $11.32, for a total value of $1,132,000.00.

Roivant Sciences Stock Up 1.1 %

Shares of ROIV opened at $10.56 on Friday. The company has a market cap of $7.69 billion, a PE ratio of 1.87 and a beta of 1.25. The business has a fifty day moving average of $11.34 and a 200 day moving average of $11.58. Roivant Sciences Ltd. has a 52-week low of $9.76 and a 52-week high of $13.06.

Roivant Sciences (NASDAQ:ROIV) last issued its quarterly earnings results on Monday, February 10th. The company reported ($0.20) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.24) by $0.04. Roivant Sciences had a negative return on equity of 14.65% and a net margin of 3,827.42%. As a group, research analysts anticipate that Roivant Sciences Ltd. will post -1.19 earnings per share for the current fiscal year.

Institutional Trading of Roivant Sciences

A number of hedge funds and other institutional investors have recently bought and sold shares of ROIV. Norges Bank purchased a new stake in Roivant Sciences in the fourth quarter worth $52,443,000. TOMS Capital Investment Management LP purchased a new stake in Roivant Sciences in the third quarter worth $46,333,000. Invesco Ltd. increased its stake in Roivant Sciences by 49.7% in the fourth quarter. Invesco Ltd. now owns 9,515,058 shares of the company’s stock worth $112,563,000 after purchasing an additional 3,159,603 shares during the period. FMR LLC increased its stake in Roivant Sciences by 5.6% in the third quarter. FMR LLC now owns 49,145,056 shares of the company’s stock worth $567,134,000 after purchasing an additional 2,593,910 shares during the period. Finally, Vanguard Group Inc. increased its stake in Roivant Sciences by 5.8% in the fourth quarter. Vanguard Group Inc. now owns 44,087,287 shares of the company’s stock worth $521,553,000 after purchasing an additional 2,404,232 shares during the period. Hedge funds and other institutional investors own 64.76% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on ROIV shares. Cantor Fitzgerald upgraded Roivant Sciences to a “strong-buy” rating in a research report on Thursday, January 30th. HC Wainwright reiterated a “buy” rating and set a $18.00 target price on shares of Roivant Sciences in a research report on Tuesday. One analyst has rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Buy” and a consensus target price of $17.93.

About Roivant Sciences

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.